Zynteglo Authorization Renewal Paused While EU Regulators Examine Safety Concerns

The European Medicines Agency is reviewing the safety of bluebird bio’s beta thalassaemia gene therapy, which is so far only approved in the EU and has only been used in one patient outside the context of clinical studies.